CA2183260A1 - Prolactine servant d'adjuvant pour vaccin - Google Patents

Prolactine servant d'adjuvant pour vaccin

Info

Publication number
CA2183260A1
CA2183260A1 CA002183260A CA2183260A CA2183260A1 CA 2183260 A1 CA2183260 A1 CA 2183260A1 CA 002183260 A CA002183260 A CA 002183260A CA 2183260 A CA2183260 A CA 2183260A CA 2183260 A1 CA2183260 A1 CA 2183260A1
Authority
CA
Canada
Prior art keywords
prolactin
composition
human
vaccine
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002183260A
Other languages
English (en)
Inventor
Susan Richards
Johanne Kaplan
Richard Moscicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2183260A1 publication Critical patent/CA2183260A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à une composition destinée à accroître la réponse immunitaire d'un animal à un vaccin de maladie infectieuse, ladite composition comprenant de la prolactine. Cette composition est de préférence de la prolactine humaine et l'animal à vacciner est également de préférence l'homme. Cette invention serapporte en outre à une composition destinée à accroître la réponse immunitaire d'un animal à un vaccin de maladie infectieuse, cette composition comprenant de l'ADNc de prolactine. De l'ADNc de prolactine humaine est préféré.
CA002183260A 1994-02-14 1995-02-14 Prolactine servant d'adjuvant pour vaccin Abandoned CA2183260A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19635094A 1994-02-14 1994-02-14
US08/196,350 1994-02-14

Publications (1)

Publication Number Publication Date
CA2183260A1 true CA2183260A1 (fr) 1995-08-17

Family

ID=22725034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002183260A Abandoned CA2183260A1 (fr) 1994-02-14 1995-02-14 Prolactine servant d'adjuvant pour vaccin

Country Status (5)

Country Link
EP (1) EP0952846A1 (fr)
JP (1) JPH09509415A (fr)
AU (1) AU700104B2 (fr)
CA (1) CA2183260A1 (fr)
WO (1) WO1995021625A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040848A1 (fr) * 1996-04-30 1997-11-06 Genzyme Corporation Utilisation de la prolactine comme un antagoniste de tgf-beta
CA2277482A1 (fr) * 1997-01-21 1998-07-23 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Stimulation de cellules hematopoietiques
WO2001014580A1 (fr) 1999-08-25 2001-03-01 Accuplex, L.L.C. Dosages diagnostiques de fluides biologiques secretes pour la detection d'etats infectieux et inflammatoires
EP1222275A2 (fr) 1999-10-22 2002-07-17 The Board of Regents of the University of Nebraska Isoforme de serum amyloide a decouverte dans le colostrum
AU2002364507A1 (en) * 2001-11-21 2003-06-10 Board Of Regents Of The University Of Nebraska Mammary-associated serum amyloid a3 promoter sequences and uses for same
US7368546B2 (en) 2003-01-21 2008-05-06 The Board Of Regents Of The University Of Nebraska Human SAA3 nucleic acid molecule, protein, and methods of use for same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725549A (en) * 1980-09-22 1988-02-16 The Regents Of The University Of California Human and rat prolactin and preprolactin cloned genes
US5028591A (en) * 1987-09-14 1991-07-02 Pitman-Moore, Inc. Method for stimulating the immune system
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect

Also Published As

Publication number Publication date
EP0952846A1 (fr) 1999-11-03
AU700104B2 (en) 1998-12-24
JPH09509415A (ja) 1997-09-22
WO1995021625A1 (fr) 1995-08-17
EP0952846A4 (fr) 1999-11-03
AU1876595A (en) 1995-08-29

Similar Documents

Publication Publication Date Title
AU734443C (en) Vaccines
US20050137130A1 (en) Medical treatment
AU702162B2 (en) Vaccine against mycobacterial infections
WO1999061068A9 (fr) Vaccins contre le cancer de la prostate, et leurs methodes de fabrication, d'utilisation, et d'evaluation
KR100773390B1 (ko) 단순 포진 바이러스 백신 키트
JP2002513811A (ja) 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入
WO1998008947A1 (fr) Amelioration de l'immunisation a l'adn obtenu a l'aide de cytokines
AU700104B2 (en) Prolactin as a vaccine adjuvant
EP1141305A1 (fr) Gene chimerique forme par les sequences d'adn codant pour les determinants antigeniques de quatre proteines de l. infantum, proteines codees par ledit gene, et compositions pharmaceutiques servant a prevenir et/ou traiter la leishmaniase chez l'animal et l'homme
KR101300905B1 (ko) 백신으로서의 생물학적 활성제와 재조합 마이코박테리움의 조합물
US6221664B1 (en) Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method
US6867000B2 (en) Method of enhancing immune responses to herpes
ES2546301T3 (es) Composición que contiene Leishmania Lip2a
CN114560917A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽TFKVSIWNL及其应用
JP4223813B2 (ja) 免疫増強特性を有するムチンペプチド
KR100568193B1 (ko) 전염성 에프 낭병의 예방을 위한 전염성 에프 낭병바이러스 항원결정부위를 포함한 ｄｎａ 백신
AU2003200723B2 (en) Encapsulated immunomodulators useful as vaccine adjuvants
WO2001029190A1 (fr) Nouveaux lymphocytes, procede de preparation de ces lymphocytes et utilisation de ces derniers dans un traitement
Hu Adjuvanticity of chicken interleukin-2 in DNA vaccines and protein vaccines delivered via microspheres
Miyagi et al. The Timing of GM-CSF Expression Plasmid
WO2000025820A1 (fr) Composes et procedes destines a l'immunisation genetique
US20100068216A1 (en) Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen
NZ627530B (en) Combination adjuvant formulation

Legal Events

Date Code Title Description
FZDE Discontinued